JP4362638B2 - ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 - Google Patents

ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 Download PDF

Info

Publication number
JP4362638B2
JP4362638B2 JP54960898A JP54960898A JP4362638B2 JP 4362638 B2 JP4362638 B2 JP 4362638B2 JP 54960898 A JP54960898 A JP 54960898A JP 54960898 A JP54960898 A JP 54960898A JP 4362638 B2 JP4362638 B2 JP 4362638B2
Authority
JP
Japan
Prior art keywords
inh
lps
cells
induced
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54960898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502367A (ja
JP2002502367A5 (fr
Inventor
クン，アーネスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of JP2002502367A publication Critical patent/JP2002502367A/ja
Publication of JP2002502367A5 publication Critical patent/JP2002502367A5/ja
Application granted granted Critical
Publication of JP4362638B2 publication Critical patent/JP4362638B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP54960898A 1997-05-13 1998-05-13 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 Expired - Fee Related JP4362638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 1997-05-13
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US09/056,396 1998-04-06
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
PCT/US1998/010033 WO1998051308A1 (fr) 1997-05-13 1998-05-13 Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009119631A Division JP2009227681A (ja) 1997-05-13 2009-05-18 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法

Publications (3)

Publication Number Publication Date
JP2002502367A JP2002502367A (ja) 2002-01-22
JP2002502367A5 JP2002502367A5 (fr) 2005-12-08
JP4362638B2 true JP4362638B2 (ja) 2009-11-11

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54960898A Expired - Fee Related JP4362638B2 (ja) 1997-05-13 1998-05-13 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法

Country Status (9)

Country Link
EP (1) EP1009404A4 (fr)
JP (1) JP4362638B2 (fr)
CN (1) CN1198614C (fr)
AU (2) AU745790B2 (fr)
BR (1) BR9809115A (fr)
CA (1) CA2289119C (fr)
IL (1) IL132758A0 (fr)
NZ (1) NZ501650A (fr)
WO (2) WO1998051308A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1140936E (pt) 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
CA2482806A1 (fr) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Derives de phthalazinone
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030891A2 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthèse d'acides gras au moyen d'inhibiteurs parp et méthodes de traitement associées
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
RU2520098C2 (ru) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
EP2377871A4 (fr) 2008-11-28 2012-07-25 Chugai Pharmaceutical Co Ltd Dérivé de 1-(2h)-isoquinolone
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
CA2992231C (fr) 2009-03-18 2022-03-29 Resverlogix Corp. Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
CA2895905A1 (fr) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Nouveaux composes heterocycliques en tant qu'inhibiteurs de bromodomaine
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
EP3655418A4 (fr) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
EP3687501A4 (fr) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004663A1 (fr) 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones utiles dans le traitement de maladies virales
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
AU5259296A (en) * 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
AU745790B2 (en) 2002-03-28
CN1261278A (zh) 2000-07-26
JP2002502367A (ja) 2002-01-22
EP1009404A1 (fr) 2000-06-21
CA2289119C (fr) 2011-03-15
CA2289119A1 (fr) 1998-11-19
IL132758A0 (en) 2001-03-19
EP1009404A4 (fr) 2009-07-01
WO1998051308A1 (fr) 1998-11-19
NZ501650A (en) 2001-11-30
BR9809115A (pt) 2002-01-02
WO1998051307A1 (fr) 1998-11-19
CN1198614C (zh) 2005-04-27
AU7484798A (en) 1998-12-08
AU7492698A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
JP4362638B2 (ja) ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
JP2009227681A (ja) ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
Chou et al. Impact of intracellular innate immune receptors on immunometabolism
Lin et al. Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents
Kang et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages
Oliver et al. Resistance to endotoxic shock as a consequence of defective NF‐κB activation in poly (ADP‐ribose) polymerase‐1 deficient mice
Chen et al. sEH inhibitor Tppu ameliorates cecal ligation and puncture-induced sepsis by regulating macrophage functions
Minodier et al. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients
Huang et al. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis
Zhang et al. Protective Effects of Oroxylin A against Doxorubicin‐Induced Cardiotoxicity via the Activation of Sirt1 in Mice
Leduc et al. The effect of local anesthetics and amitriptyline on peroxidation in vivo in an inflammatory rat model: preliminary reports
Kones et al. Current treatment of dyslipidemia: evolving roles of non-statin and newer drugs
Dravid et al. Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
CN113768917A (zh) 木犀草素在抑制nlrp3炎症小体活化中的应用
Chen et al. Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors
Batiha et al. Management of SARS-CoV-2 infection: key focus in macrolides efficacy for COVID-19
Tao et al. Exploring the mechanism through which Phyllanthus emblica L. Extract exerts protective effects against acute gouty arthritis: a network pharmacology study and experimental validation
AU2007308742A1 (en) Combination therapy
Li et al. Dose–effect of irbesartan on cyclooxygenase-2 and matrix metalloproteinase-9 expression in rabbit atherosclerosis
EP2107907B1 (fr) Combinaison de pémirolast et ramatrobane pour l'utilisation dans le traitement de troubles inflammatoires
Williams et al. Interleukin‐1β (IL‐1β) inhibition: a possible mechanism for the anti‐inflammatory potency of liposomally conjugated methotrexate formulations in arthritis
MXPA99010417A (en) METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
Che et al. Preparation of betaine injection and its therapeutic effect in pulmonary arterial hypertension
Brahn et al. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458
KR20210096588A (ko) ox-LDL의 분해를 위한 거품세포의 자가포식 촉진에서 푸코산 설페이트의 응용

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090730

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130828

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees